ストックスクリーナーアプリを入手
19.39
3.75%
0.70
アフターアワーズ：
19.39
Newamsterdam Pharma Company Nv (NAMS) 最新ニュース
Cantor Fitzgerald initiates overweight rating for NewAmsterdam Pharma stock - Investing.com
Cantor Fitzgerald Initiates NewAmsterdam Pharma Overweight With $42 Price Target - marketscreener.com
RBC Capital maintains outperform rating for NewAmsterdam Pharma stock By Investing.com - Investing.com South Africa
RBC Capital maintains outperform rating for NewAmsterdam Pharma stock - Investing.com India
Northern Trust Corp Takes $556,000 Position in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Rating Increased to Hold at Wall Street Zen - Defense World
(NAMSW) Proactive Strategies - news.stocktradersdaily.com
Shareholders Will Probably Not Have Any Issues With NewAmsterdam Pharma Company N.V.'s (NASDAQ:NAMS) CEO Compensation - simplywall.st
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June - The Manila Times
NewAmsterdam Pharma CEO to Present at William Blair, Jefferies, and Goldman Sachs Healthcare Conferences - Stock Titan
NewAmsterdam Pharma (NASDAQ:NAMS) Given Consensus Recommendation of “Buy” by Analysts - Defense World
(NAMS) Technical Pivots with Risk Controls - news.stocktradersdaily.com
NewAmsterdam Pharma’s SWOT analysis: obicetrapib stock poised for cardiovascular market By Investing.com - Investing.com South Africa
NewAmsterdam Pharma’s SWOT analysis: obicetrapib stock poised for cardiovascular market - Investing.com Canada
35,657 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Purchased by BNP Paribas Financial Markets - Defense World
Financial Contrast: NewAmsterdam Pharma (NAMS) versus Its Rivals - Defense World
(NAMSW) Investment Analysis - news.stocktradersdaily.com
The Manufacturers Life Insurance Company Purchases New Position in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Tower Research Capital LLC TRC Sells 6,485 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Wall Street Analysts Predict a 132.5% Upside in NewAmsterdam Pharma Company N.V. (NAMS): Here's What You Should Know - MSN
NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference - GlobeNewswire
NewAmsterdam Pharma Showcases Non-Statin CVD Pipeline at Major RBC Healthcare Conference - Stock Titan
(NAMS) Proactive Strategies - news.stocktradersdaily.com
Analysts Have Been Trimming Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Price Target After Its Latest Report - simplywall.st
Barclays PLC Buys 9,117 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Needham & Company LLC Issues Pessimistic Forecast for NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price - Defense World
NewAmsterdam Pharma Reports Q1 2025 Financial Results - TipRanks
NewAmsterdam Pharma Q1 Net Loss Narrows, Revenue Rises - marketscreener.com
NewAmsterdam Pharma Company NV reports results for the quarter ended March 31Earnings Summary - TradingView
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results - GlobeNewswire
Ratios Revealed: Decoding NewAmsterdam Pharma Company NV (NAMS)’s Financial Health - DWinneX
Earnings Flash (NAMS) NewAmsterdam Pharma Co. NV Reports Q1 Revenue $2.98M, vs. FactSet Est of $1.6M - marketscreener.com
Earnings Flash (NAMS) NewAmsterdam Pharma Co. NV Reports Q1 Revenue $3M, vs. FactSet Est of $1.6M - marketscreener.com
NewAmsterdam Pharma Q1 2025 Financial Results and Corporate Update - TradingView
Envestnet Asset Management Inc. Sells 8,738 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma Announces Late-Breaking Data from - GlobeNewswire
NewAmsterdam Pharma (NAMS) Reveals Promising Phase 3 Study Results for Obicetrapib | NAMS Stock News - GuruFocus
NewAmsterdam Pharma Presents Promising Phase 3 Trial Data - TipRanks
NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025 - marketscreener.com
Trend Tracker for (NAMS) - news.stocktradersdaily.com
Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) PT at $43.33 - Defense World
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma Expands Clinical Team with 11 New Hires, Awards $4M in Equity Grants - Stock Titan
Examining NewAmsterdam Pharma Company NV (NAMS) stock is warranted - uspostnews.com
NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress - GlobeNewswire
Major Breakthrough: NewAmsterdam Reveals Multiple Phase 3 Trial Results for Novel Heart Drug - Stock Titan
Geode Capital Management LLC Raises Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma Company N.V. (NAMS): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential - Insider Monkey
Legal & General Group Plc Acquires 4,556 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
0.00%
0.54%
大文字化:
|
ボリューム (24 時間):